Finland Biotech Biotie Therapies has reached an agreement with the FDA regarding the design of its Phase III trial for its Parkinson's disease treatment tozadenant.
The late-stage trial will be conducted under a Special Protocol Assessment that will include 450 Parkinson's disease patients over 24 weeks. Patients in the study will receive twice daily...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?